Daiichi Sankyo Company, Limited

Sapporo Medical University

Kazusa Dna Research Institute Foundation

Daisuke Okajima

Hirofumi Hamada

Takeshi Masuda

Kensuke Nakamura

Hiroaki Uchida

Takashi Nakada

Yusuke Ota

Shinji Ashida

Mitsuhiro Iwamoto

Narihiro Toda

Ichiro Hayakawa

Tomoko Terauchi

Masaki Meguro

Fuminao Doi

Naoya Harada

Jun Hasegawa

Toshinori Agatsuma

Shu Takahashi

Miki Yamaguchi

Hiroshi Yokota

Osamu Ohara

Takahiro Nagase

Michio Ohishi

Shigeru Noguchi

Satoru Yasuda

Ken Sakurai

Kei Enomoto

The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate

A method for identifying a subject to whom a medicament containing an anti-hTROP2 antibody is to be given, wherein the subject is a human patient suffering from a cancer, comprising: obtaining a biological sample from the human patient diagnosed as suffering from a cancer; evaluating an amount of expression of the hTROP2 gene at mRNA level in the biological sample; evaluating an amount of expression of the SLFN11 gene at mRNA level in the biological sample, wherein the biological sample is one that is determined to have a high amount of expression of the hTROP2 gene; and identifying the human patient who provided the biological sample, wherein the biological sample is one that is determined to have a high amount of expression of the SLFN11 gene, as a subject to whom a medicament containing an anti-hTROP2 antibody is to be given.

Sensitivity marker for antibody-drug conjugate

Provided are novel antibody-pyrrolodiazepine derivative and novel antibody-pyrrolodiazepine derivative conjugates, as well as methods of using the same, and a novel CLDN6 and/or CLDN9 antibody. The disclosed compounds are of the class of alkyl benzene sulfonyl ureas, useful as oral anti-diabetics, and include substituted benzo[e]pyrrolo[1,2-α][1,4]diazepine.

Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines

A novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines represented by the [Formula 24], [Formula 25], [Formula 26], and/or [Formula 27].

Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-&#x3b1;][1,4]diazepines

Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor

A method for producing an antibody-drug conjugate composition, comprising: (i) a step of reacting an antibody with a reducing agent in a buffer to reduce interchain disulfides, and (ii) a step of reacting drug linker intermediates with the antibody having thiol groups obtained in the step (i), wherein the reaction temperature in the step (i) is &#x2212;10&#xb0; C. to 10&#xb0; C., and the average number of bound drugs in the produced antibody-drug conjugate composition is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, in the produced antibody-drug conjugate composition is 50% or more; and an antibody-drug conjugate composition, wherein the content of antibody-drug conjugates wherein the average number of bound drugs is 3.5 to 4.5, and the content of antibody-drug conjugates in which four drug linkers are bound to heavy-light interchain thiols, is 50% or more.

Method for selectively manufacturing antibody-drug conjugate

It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; wherein the anti-TROP2 antibody is connected to the terminal of L, and the antitumor compound is connected to the carbonyl group of the &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety with the nitrogen atom of the amino group at position 1 as a connecting position.

Anti-TROP2 antibody-drug conjugate

DNA encoding a cholecystokinin octapeptide sulfated form (CCK-8S) G-protein coupled receptor, a complementary strand thereof, a vector containing the DNA, a transformant containing the vector, a pharmaceutical composition, and a reagent kit are provided. Such DNA and constructs are useful in identifying a compound that inhibits or promotes a function of the protein and/or expression of a DNA encoding the protein. Such DNA and constructs are also useful for identifying an anti-depressant drug or a compound that has an anti-depressant action.

DNA encoding a CCK-8S G-protein coupled receptor, and vectors, transformants, cell kits, and methods employing such DNA

Methods of providing a protein having a function as a G-protein coupled receptor and methods of identifying a compound that inhibits or promotes a function of the protein and/or expression of a DNA encoding the protein are provided. Methods for identifying an anti-depressant drug or a compound That has an anti-depressant action and methods for diagnosing depression are also provided.

Assay employing a g-protein coupled receptor that is activated by CCK-8S

Growing community of inventors

Tokyo, Japan

Daisuke Okajima